Asset Details
Do you wish to reserve the book?
High vs low CPAP strategy with aerosolized calfactant in preterm infants with respiratory distress syndrome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
High vs low CPAP strategy with aerosolized calfactant in preterm infants with respiratory distress syndrome
Do you wish to request the book?
High vs low CPAP strategy with aerosolized calfactant in preterm infants with respiratory distress syndrome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
High vs low CPAP strategy with aerosolized calfactant in preterm infants with respiratory distress syndrome
2025
Overview
Background
Optimal CPAP strategy to prevent CPAP failure defined as need for endotracheal intubation is unknown.
Objective
To evaluate the risk of CPAP failure in infants treated with high vs low CPAP strategy while receiving aerosolized calfactant in the AERO-02 clinical trial and AERO-03 expanded access program.
Methods
Infants born between 29 0/7 to 36 6/7 weeks were included. Comparisons were made between low and high CPAP groups (Low, 4–7 cm H
2
O; High, 8–10 cm H
2
O).
Results
CPAP failure and pneumothorax were not different between the groups. Odds of CPAP failure were not different after adjustment for baseline characteristics (OR = 0.61; 95% CI: 0.29, 1.24).
Conclusion
We found no difference in CPAP failure among infants who received aerosolized calfactant that were treated with high vs low CPAP strategy. Efficacy of high CPAP strategy with aerosolized surfactant treatment needs to be evaluated in future studies.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
/ Aerosols
/ Biological Products - administration & dosage
/ Biological Products - therapeutic use
/ Continuous Positive Airway Pressure
/ Failure
/ Female
/ Humans
/ Infants
/ Male
/ Medicine
/ Pulmonary Surfactants - administration & dosage
/ Respiratory distress syndrome
/ Respiratory Distress Syndrome, Newborn - therapy
/ Strategy
